Image pharmaphorum Editor News Pain Therapeutics' opioid drug fails to gain FDA approval The US regulator has rejected Pain Therapeutics' abuse-deterrent opioid painkiller drug, Remoxy, for the fourth time. Market Access FDA grants leukaemia drug ‘breakthrough’ status A leukaemia drug has been granted ‘breakthrough therapy’ status by the US drug regulator. News New tuberculosis drug could help eradicate global killer A groundbreaking drug, rifampin, could help to end the global tuberculosis epidemic, according to researchers. News Takeda finalises buyout of TiGenix Japanese pharma giant Takeda has completed its buyout of TiGenix. Load more results
News Pain Therapeutics' opioid drug fails to gain FDA approval The US regulator has rejected Pain Therapeutics' abuse-deterrent opioid painkiller drug, Remoxy, for the fourth time.
Market Access FDA grants leukaemia drug ‘breakthrough’ status A leukaemia drug has been granted ‘breakthrough therapy’ status by the US drug regulator.
News New tuberculosis drug could help eradicate global killer A groundbreaking drug, rifampin, could help to end the global tuberculosis epidemic, according to researchers.
News Takeda finalises buyout of TiGenix Japanese pharma giant Takeda has completed its buyout of TiGenix.
News FDA clears first all-oral combo for first-line CLL treatment AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
